|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Lung Resource Center, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
Correspondence to: R. A. Stockley, MD, DSc, Lung Resource Center, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK; e-mail: r.a.stockley{at}bham.ac.uk
Key Words:
1-antitrypsin deficiency chemoattractant COPD elastase emphysema interleukin-8 leukotriene B4 neutrophil
The polymorphonuclear leukocyte is a key effector cell of the secondary host defense system. This cell, however, also has been implicated in the pathogenesis of chronic lung disease for > 30 years. The association dates to an observation in 1963 that severe early-onset emphysema was associated with deficiency in
1-antitrypsin (
1-AT).1
The recognition that
1-AT was a serum protein that functioned as an endogenous inhibitor of serine proteinases suggested that an enzyme or enzymes, the activity of which normally was regulated by
1-AT, was responsible for the lung damage leading to emphysema. This chance observation led to the proteinase/antiproteinase theory of the pathogenesis of emphysema that is now accepted widely as a key mechanism of disease development.
Broadly, the theory states that the release of proteolytic enzymes within the lungs in healthy subjects is normally prevented from causing lung damage by a protective "screen" of antiproteinases. When the protective screen is deficient or when the enzyme load exceeds the capacity of the antiproteinases to protect the tissues, proteolytic lung destruction ensues.
| The Neutrophil |
|---|
|
|
|---|
1-AT is a serum inhibitor of serine proteinases, although it also provides an effective antiproteinase screen in the alveolar region2
and, by inference, in the lung interstitium. Studies in vivo have shown that two serine proteinases, elastase and proteinase-3, which are released by neutrophils,3
4
can induce in animals pathologic changes that resemble human emphysema. Furthermore, neutrophil sequestration in the pulmonary circulation also will lead to the development of emphysema in dogs.5
These studies, therefore, confirm that the neutrophil and its proteinases have the potential to produce human emphysema.
More recently, the neutrophil also has been implicated in other manifestations of COPD since experimental application of neutrophil elastase (NE) can reproduce many of the features of patients with this syndrome. For instance, the aerosol administration of NE to guinea pigs can produce extensive epithelial damage that occurs within 20 min of contact.6
The damage and subsequent repair is consistent with the loss of ciliated epithelium and squamous metaplasia seen in the major bronchi in human patients with COPD. Furthermore, NE reduces the ciliary beat frequency of the human respiratory epithelium in vitro,7
which is consistent with the reduced mucociliary clearance that is seen in COPD patients.8
The instillation of NE into the airways leads to mucous gland hyperplasia in hamsters,9
and the enzyme is a major mucus secretagogue in bovine airway serous gland cells.10
Such observations suggest important roles for NE in the bronchitis pathology and mucus expectoration of some COPD patients. Indeed, clinical studies have shown a direct relationship between the volume of sputum expectorated daily and the NE content of the secretions (Fig 1
). Finally, NE can impair many other important host defenses that may, in part, be responsible for bacterial colonization in a proportion of patients. Despite these theoretical mechanisms, however, only a few patients have
1-AT deficiency, and, thus, it has been difficult to explain why the lung is not normally protected in the majority of COPD patients.
|
| Neutrophil Differentiation and Migration |
|---|
|
|
|---|
| Neutrophils in COPD |
|---|
|
|
|---|
|
1-AT deficiency have suggested that the major chemoattractant in the peripheral airways of these patients is leukotriene (LT) B4.17
In
1-AT-deficient subjects, the mechanism thought to be important is the failure to inhibit NE that is released within the airway. Studies have shown that NE activity can stimulate macrophages to release LTB4.17
This leads to an amplification of neutrophil recruitment that is believed to be the cause of the development of early emphysema in these patients. Furthermore, recent preliminary studies indicate that IL-8 levels also are increased in the BAL fluid samples obtained from patients with
1-AT deficiency early in the development of the disease.18
This suggests that more than one chemoattractant may be involved in neutrophil migration in patients with
1-AT deficiency.
Secretions obtained more proximally in the bronchial tree also have been shown to contain LTB4 and IL-8, and, moreover, secretions from this site also have higher concentrations of LTB4 in patients with
1-AT deficiency than in patients with COPD that is not due to
1-AT deficiency.19
This suggests further that a failure to inhibit bronchial NE activity leads to stimulation of the release of macrophage LTB4, which may be a pivotal mediator of neutrophil migration in vivo (Fig 3
).
|
Other factors that are important in cell migration include the expression of adhesion molecules on the vascular endothelium. Pathologic studies21 have shown that endothelial cell expression levels of E-selectin (which is necessary for slowing down circulating neutrophils) are increased in patients with COPD. Furthermore, they showed that the degree of endothelial E-selectin expression was related to the tissue neutrophil content. Other studies have reported an increase in the number of circulating adhesion molecules,22 suggesting that neutrophils and the endothelium have been activated, and this is supported by the observation that the neutrophils demonstrate an increased surface expression of Mac 1 (CD11b).23
| Susceptibility |
|---|
|
|
|---|
1-AT deficiency because of a defective protective antiproteinase screen within the lung. However, as intimated previously, the majority of patients with COPD and emphysema appear to have normal circulating concentrations, and therefore lung concentrations of,
1-AT. Previous studies24
have suggested that the inactivation of
1-AT within the lung secretions, possibly by oxidation of its active site by oxidants in cigarette smoke, may explain the development of proteinase-mediated lung damage. However, this concept remains unable to explain susceptibility because the inactivation of
1-AT by this mechanism is a simple biochemical process and, therefore, would be expected to occur in all smokers.
Studies have helped to explain how neutrophils cause connective tissue damage and, potentially, all the elastase-mediated pathologic changes. The NE is stored within neutrophil azurophil granules, where its concentration has been estimated at approximately 5 mM. Following neutrophil activation, the granules undergo exocytosis, and the enzyme diffuses away from the granule, its concentration dropping as it does so. Inhibitors such as
1-AT and secretory leukoproteinase inhibitor inactivate NE on a 1:1 mol/L basis. The concentrations of these inhibitors within the lung interstitium are unknown, however,
1-AT, for instance, is a freely diffusible molecule, and the serum protein albumin (which is the same molecular size as
1-AT) is thought to be present in the interstitium at approximately 80% of the concentration in the serum.25
Since the serum concentration of
1-AT in healthy subjects is approximately 30 µM, the predicted concentration in the interstitium should be approximately 24 µM, which is some 200 times lower than the concentration of elastase in the azurophil granule. Thus, NE has to diffuse away from the granule until the concentration has fallen sufficiently for the enzyme to be completely inactivated by the local concentration of
1-AT. The relationship between the concentration of elastase and the distance away from the azurophil granule has been predicted to be exponential.26
There is a rapid fall in concentration until it reaches approximately 11 µM, and, thereafter, the concentration falls more slowly.
This theoretical relationship may explain not only the tissue destruction that occurs in the absence of
1-AT deficiency, but also the extensive destruction seen in deficient subjects. First, the release of NE in such high concentrations means that some tissue destruction will always occur at the site of release. Indeed, this may well be an important factor in facilitating cell migration through the tight connective tissue matrix. Normal concentrations of
1-AT restrict the area of damage, whereas the serum concentration is 5 µM in patients with
1-AT deficiency (by inference, the interstitial concentration would be 4 µM), a level that is below the threshold on the exponential curve of NE concentration to distance diffused away from the azurophil granule (Fig 4
).
|
1-AT deficiency a degree of tissue damage will always occur in the immediate vicinity of a degranulating neutrophil. When the
1-AT concentrations are significantly reduced (as in patients with
1-AT deficiency), the area of damage that will occur can be predicted to be far greater. This would explain not only the increased susceptibility of patients with
1-AT deficiency to tissue damage, but it also provides an explanation for the development of similar but limited damage in non-
1-AT-deficient subjects. Thus, it is likely that the factors of key importance in the susceptibility of individuals to the development of the pathologic changes of COPD in cases of emphysema are the size of the neutrophil traffic and the period of time over which it occurs. With this concept in mind, there are several factors that have been identified that could influence the process. First, as indicated earlier, McCrea and colleagues16 demonstrated that the lung concentration of IL-8 was increased above the normal range in a small number of healthy smokers. It would, therefore, be predicted that in these individuals a greater amount of neutrophil traffic would occur. The mechanisms have yet to be elucidated, but studies have indicated that cigarette smoke can lead to the release of IL-8 from airway epithelial cells,27 and it is possible that, in the susceptible individual, an increased response to such a stimulus takes place.
An alternative explanation has been suggested by studies from Burnett et al28 who demonstrated that neutrophils from patients with chronic bronchitis and airflow obstruction were more sensitive to chemotactic stimuli and, when activated, had greater potential to cause connective tissue damage. If this phenomenon is a primary event, the release of normal concentrations of chemoattractants in the lungs of such individuals can be postulated to lead to an amplified neutrophil response and to more extensive tissue damage, which could explain their susceptibility to the development of COPD. The exact mechanisms of the neutrophil activation have yet to be determined, although subsequent studies by the same group29 have indicated that the neutrophils overexpressed cell surface chemokine receptors.
Understanding the mechanisms that lead to increased susceptibility should permit the development of new therapeutic strategies. It may be possible to down-regulate the chemoattractants if they are being overexpressed or, alternatively, to deactivate or desensitize the neutrophil to normal chemoattractants.
| Role of Neutrophils in Exacerbations |
|---|
|
|
|---|
Studies, however, indicate that colonization of the airways per se is not a major stimulus to neutrophil recruitment. Indeed, because of effective local host defense, it is possible to retain sterility of the airways and to ensure that bacterial numbers remain low. There is, however, a clear relationship between the size of the colonizing microbial load in the airway and the neutrophilic response.37 Furthermore, once the neutrophilic response has occurred, there is an obvious change in the sputum, in that its color changes from clear or white to yellow or green, and this is related directly to the myeloperoxidase released from the recruited neutrophils. Indeed, if samples from patients are assessed by their purulent nature alone, the incidence of a positive bacterial culture rises dramatically to 80 to 100%.34
During these exacerbations related to bacterial infection, there is an increase in the concentrations of chemoattractants. In mild episodes, it is likely that LTB4 is the major neutrophil chemoattractant.38 However, as an exacerbation increases in severity, there is also a dramatic increase in IL-8 levels.39 The recruitment of neutrophils during these episodes results in an increased level of free elastase activity in the airways, and this has the potential to cause the manifestations of bronchial damage that were discussed previously. This concept has been confirmed, in that exacerbations of COPD associated with clear or mucoid sputum are not associated with a change in bacteriology or neutrophil recruitment, whereas exacerbations that are clearly associated with increased mucus purulence are associated with an increased incidence of bacterial isolation, and a two- to three-order of magnitude increase in the numbers of bacteria.34
Isolated as well as recurrent exacerbations may be associated with a deterioration in health status.40 At present, however, it is unknown whether the exacerbations associated with neutrophil recruitment alone are responsible, or whether declining health status is a feature of all exacerbations. However, of more importance, neutrophilic exacerbations are associated with increased free elastase activity38 and, hence, with the potential for further bronchial damage. It remains possible that recurrent purulent exacerbations may be responsible for the progression of lung disease, and this possibility is worthy of further study.
| Summary |
|---|
|
|
|---|
1-AT deficiency, the size and extent of neutrophil traffic is of major pathogenic importance. Understanding the mechanisms involved should lead to the design of appropriate therapeutic strategies. The site of neutrophil recruitment may determine the individual pathologic features of COPD.
| Footnotes |
|---|
1-AT =
1-antitrypsin; IL = interleukin; LT = leukotriene; NE = neutrophil elastase | References |
|---|
|
|
|---|
1-globulin pattern of serum in
1-antitrypsin deficiency. Scand J Clin Lab Invest 15,132-140[CrossRef][ISI]
1-antitrypsin deficiency: spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 88,891-897
1-antitrypsin deficiency [abstract]. Chest 117,250S-251S
1-antitrypsin deficiency. Eur Respir J 15,886-890[Abstract]
B activation and IL-8 mRNA expression in guinea pigs in vivo. Am J Respir Cell Mol Biol 20,189-198This article has been cited by other articles:
![]() |
J. Holme and R. A. Stockley Radiologic and Clinical Features of COPD Patients With Discordant Pulmonary Physiology: Lessons From {alpha}1-Antitrypsin Deficiency Chest, September 1, 2007; 132(3): 909 - 915. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamagata, H. Sugiura, T. Yokoyama, S. Yanagisawa, T. Ichikawa, K. Ueshima, K. Akamatsu, T. Hirano, M. Nakanishi, Y. Yamagata, et al. Overexpression of CD-11b and CXCR1 on Circulating Neutrophils: Its Possible Role in COPD Chest, September 1, 2007; 132(3): 890 - 899. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tsoumakidou, E. Papadopouli, N. Tzanakis, and N. M. Siafakas Airway Inflammation and Cellular Stress in Noneosinophilic Atopic Asthma Chest, May 1, 2006; 129(5): 1194 - 1202. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Simpson, R. J. Scott, M. J. Boyle, and P. G. Gibson Differential Proteolytic Enzyme Activity in Eosinophilic and Neutrophilic Asthma Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 559 - 565. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. S. Woolhouse, D. L. Bayley, P. Lalor, D. H. Adams, and R. A. Stockley Endothelial interactions of neutrophils under flow in chronic obstructive pulmonary disease Eur. Respir. J., April 1, 2005; 25(4): 612 - 617. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Lappalainen, J. A. Whitsett, S. E. Wert, J. W. Tichelaar, and K. Bry Interleukin-1{beta} Causes Pulmonary Inflammation, Emphysema, and Airway Remodeling in the Adult Murine Lung Am. J. Respir. Cell Mol. Biol., April 1, 2005; 32(4): 311 - 318. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Young, R. D. Thompson, K. Y. Larbi, M. La, C. E. Roberts, S. D. Shapiro, M. Perretti, and S. Nourshargh Neutrophil Elastase (NE)-Deficient Mice Demonstrate a Nonredundant Role for NE in Neutrophil Migration, Generation of Proinflammatory Mediators, and Phagocytosis in Response to Zymosan Particles In Vivo J. Immunol., April 1, 2004; 172(7): 4493 - 4502. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A Dougherty, B. L Didur, and L. S Aboussouan Long-Acting Inhaled {beta}2-Agonists for Stable COPD Ann. Pharmacother., September 1, 2003; 37(9): 1247 - 1255. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. H. Chan, D. K. Y. Shum, and M. S. M. Ip Sputum Sol Neutrophil Elastase Activity in Bronchiectasis: Differential Modulation by Syndecan-1 Am. J. Respir. Crit. Care Med., July 15, 2003; 168(2): 192 - 198. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Kolls, S. T. Kanaly, and A. J. Ramsay Interleukin-17: An Emerging Role in Lung Inflammation Am. J. Respir. Cell Mol. Biol., January 1, 2003; 28(1): 9 - 11. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |